News

Nanotechnology bio applications in the clinical diagnosis: nanoplasmodic biosensor device for the early diagnosis of colorectal cancer

The group of Nano-biosensors and Bioanalytical applications of CIBER-BBN which coordinates Unit 4 of NANBIOSIS directed by Dr. Laura Lechuga, has led the final preparations of a technology with potential application in the early diagnosis of colorectal cancer, based in the detection of specific biomarkers in blood.
The nanoplasmonic biosensor based on LSPR (Localized Surface Plasmon Resonance) is generated on structured surfaces of nano discs of gold, that allow monitoring of biological interactions in real time and without the need of markers.
The nanoplasmonic biosensor allows analysis of human samples in a few minutes, without requiring reagents or additional instrumentation. The device is easy to use and its reduced dimensions offer an attractive opportunity for the development of point-of-care devices with potential to be used outside the laboratory.

Article of Reference: Label-free nanoplasmonic sensing of tumor-associate autoantibodies for early diagnosis of colorectal cancer.Maria Soler, M. Carmen Estevez, Roi Villar-Vázquez, J. Ignacio Casal, Laura M. Lechuga. Analytica Chimica Acta. http://dx.doi.org/10.1016/j.aca.2016.04.059

Nanotechnology bio applications in the clinical diagnosis nanoplasmodic biosensor device for the early diagnosis of colorectal cancer

• Read More

Synergies produced in NANBIOSIS multiply the value of its services and allow its users to have results with faster and superior reliability due to proven experience of the scientists and technicians involved, says Jaume Veciana, Scientific Director of NANBIOSIS, in an interview at July 2016 CIBER-BBN Bulletin.

In this interview, Jaume Veciana assesses the functioning of this Singular Scientific-Technical Infrastructure and its contribution to research and anticipates some of the guidelines of the NANBIOSIS Strategic Plan 2017-2020, which includes a clear commitment to internationalization.

“The scientific-technical capabilities available at NANBIOSIS must be exploited without limitation to our country. Therefore we are clear that we must promote the activity of NANBIOSIS both academic and industrial sector in the European Union and other countries, either directly or in association with other similar organizations actions. Some such initiatives have already started but we believe it should be given further boost to internationalization. As an example we can mention the participation in the European project INFRAIA that aims to integrate regional and national research infrastructures existing in Europe under the Horizon 2020”

Professor Veciana also talks about NANOMOL, the research group coordinator of Unit 6 of NANBIOSIS, and the main applications of their findings in the fields of nanomedicine and biomaterials.

To know more

Synergies produced in NANBIOSIS multiply the value of its services and allow its users to have results with faster and superior reliability due to proven experience of the scientists and technicians involved, says Jaume Veciana, Scientific Director of NANBIOSIS, in an interview at July 2016 CIBER-BBN Bulletin.

• Read More

Dr. Simó Schwartz, Scientific Director of Unit 20 of NANBIOSIS: appointed president of the European Society for Nanomedicine (ESNAM) and member of the executive board of the International Society of Nanomedicine (ISN).

The objectives of ESNAM are to promote nanomedicine research and facilitate the exchange of knowledge among its members (currently, about 800 members). According to Dr. Simó Schwartz “the dissemination of specialized infrastructure in nanomedicine, like NANBIOSIS, among members of the society and its utilities is also an object of ESNAM. This is intended to strengthen European technological capabilities, use, and improvement of clinical transfer”.

Society members represent different sectors of the scientific community: doctors, biologists, chemists, pharmacists, physical …. The technical office of the ESNAM in Barcelona is located in the Vall d’Hebron Hospital and is coordinated by Aida Castellanos, CIBER-BBN R&D+i Project Manager.

In addition, Dr. Schwartz has also been appointed a member of the executive board of the International Society of Nanomedicine (ISN), a newly established company that includes the American Association, Korean and European, ESNAM, among others. This entity will organize the 2nd year of summer in Barcelona Nanomedicine 2017, this year held in South Korea.

Dr. Simó Schwartz, Scientific Director of Unit 20 of NANBIOSIS: appointed president of the European Society for Nanomedicine (ESNAM) and member of the executive board of the International Society of Nanomedicine (ISN).

• Read More

Pablo Laguna and Jordi Aguilo, Scientific Directors of the Units 27 and 8 of NANBIOSIS participate in the European program Remote Assessment of Disease and Relapse in Central Nervous System Disorders (RADAR-CNS)

RADAR-CNS is an important European research program supported by the Innovative Medicines Initiative (IMI) focused to develop new ways of monitoring patients affected by major depression, epilepsy and multiple sclerosis, with the use of wearable technology and smart mobile phones.

This program brings together experts from various disciplines in clinical research, engineering, computer and data analysis, as well as health services. RADAR-CN aims to improve symptoms and quality of life of patients and treatment of these and other chronic diseases. This program is jointly led by King’s College London and the pharmaceutical company Janssen and is funded by the Innovative Medicines Initiative (a public-private agreement EFPIA and the European Union). RADAR-CNS involves 24 organizations in Europe and US, including CIBER through its thematic areas of Mental Health (CIBERSAM) and Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN)

“In recent years, the quality and quantity of data that can be collected with the wearable technology and smart phones has increased a lot. The information generated with this large amount of data will help to improve clinical care by providing greater detail of the patient’s condition and prognosis of its evolution. Moreover, it will be possible to detect whether a patient is beginning to have problems before there is clinical evidence of it” says Dr. Jordi Aguilo, scientific coordinator of the Unit 8 of NANBIOSIS.

This huge generate data sets, suitable to be stored and treated so to retrieve the relevant information hidden in the data, frequently require computing systems and information systems of high performance. The Unit 27 of NANBIOSIS will be the platform in which this analysis will be performed.

Pablo Laguna and Jordi Aguilo, Scientific Directors of the Units 27 and 8 of NANBIOSIS participate in the European program Remote Assessment

• Read More

Elizabeth Engel, Scientific Coordinator of Unit 5 of NANBIOSIS: “Our research has opened the door to the regeneration of the nervous system by biomaterials”

The CIBER-BBN research group Biomaterials for Regenerative Therapies, which coordinates Unit 5 of NANBIOSIS develops various lines of research on biomaterials for regenerative therapies, especially focusing on the design and fabrication of scaffolds for tissue regeneration. They are working with polymers, hydrogels and compounds that can be manufactured using different techniques such as electrospinning to make 3D printing matrices or scaffolding. Applications are diverse, such as bone regeneration, neuronal, skin or cell therapy.

The group has recently presented the results of a project focused on the development of implants for the regeneration of nerve tissue with very promising results. The study opens the door to the possibility of regenerating the nervous system, since the capacity of cells to dedifferentiate is demonstrated and thus become capable of generating tissue cells. Moreover, these nanofibers scaffolds benefits vascularization (generation of new blood vessels) in the injured area, which promotes regeneration. The study has been shown in laboratory mouse and currently Dr. Alcantara (University of Barcelona), with whom the group is collaborating on this project since 6 years ago, is doing tests in rats to show that new neurons generated are functional.

The new prospects for medicine opened by this finding are very important: The first is the regenerative capacity of the brain. The second, biomaterials play a fundamental role in this regeneration and can open an important way for the development of biomedical devices that advance tissue regeneration using whose regulatory systems to market is much less complex than advanced therapies based cells and growth factors. 3D printing opens a new approach to fabricate this type of implants, as more porous structures can be printed to favor cell colonization and vascularization.

Elizabeth Engel, Scientific Coordinator of Unit 5 of NANBIOSIS: “Our research has opened the door to the regeneration of the nervous system by biomaterials”

• Read More

“a-Galactosidase A Loaded Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration”

Unit 1 of NANBIOSIS, Protein Production Platform (PPP), Unit 3, Synthesis of Peptides, Unit 20, In Vivo Experimental Platform and Unit 6, Biomaterial Processing and Nanostructuring Unit, have jointly developed the research conducted in relation with a CO2-based methodology for the one-step production of protein-nanoliposome conjugates as bio-active nanomaterials with therapeutic interest. The results have been published in Advanced Healthcare Materials: http://www.ncbi.nlm.nih.gov/pubmed/26890358

“a-Galactosidase A Loaded Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration I. Cabrera, I. Abasolo, J. L. Corchero, E. Elizondo, P. Rivera, E. Moreno, J. Faraudo, S. Sala, D. Bueno, E. González-Mira, M. Rivas, M. Melgarejo, D. Pulido, F. Albericio, M. Royo, A. Villaverde, M. F. García-Parajo, S. Schwartz Jr., N. Ventosa,*, and J. Veciana,*

Lysosomal storage disorders (LSD) are caused by lysosomal dysfunction usually as a consequence of deficiency of a single enzyme required for the metabolism of macromolecules such as lipids, glycoproteins and mucopolysaccharides. For instance, the lack of alpha-Galactosidase A (GLA) activity in Fabry disease patients causes the accumulation of glycosphingolipids in the vasculature leading to multiple organ pathology.

Enzyme replacement therapy (ERT), which is the most common treatment of LSD, exhibits several drawbacks mainly related to the instability and low efficacy of the exogenously administered therapeutic enzyme. In this work, the unprecedented increased enzymatic activity and intracellular penetration achieved by the association of a human recombinant GLA to nanoliposomes functionalized with RGD peptides is reported. Moreover, these new GLA loaded nanoliposomes lead to a higher efficacy in the reduction of the GLA substrate named globotriasylceramide (Gb3) in a cellular model of Fabry disease, than that achieved by the same concentration of the free enzyme. The preparation of these new liposomal formulations by DELOS-SUSP, based on the Depressurization of a CO2-Expanded Liquid Organic Solution, shows the great potential of this CO2-based methodology for the one-step production of protein-nanoliposome conjugates as bioactive nanomaterials with therapeutic interest.

“a-Galactosidase A Loaded Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration”

• Read More

NANBIOSIS participated in the CTLS 2016 Conference.

Jesús Izco, Coordinator of NANBIOSIS participated in Core Technologies for Life Science 2016 that took place last 12 – 15 Jun at EMBL in Heidelberg, Germany, taking a unique opportunity to listen and discuss with colleagues and peers about challenges and solutions on all aspects of core facilities and infrastructures. Special mention requires the meeting with Patrick England coordinator of ARBRE, to treat NANBIOSIS participation in the V work package of Cost Action MOBIEU.

CTLS 2016 brought together not only scientists, technicians and managers, but also decision makers and opinion leaders involved in Core Technology facilities and resource laboratories in all fields of Life Science.

At the conference the following topics were discussed:
• New technologies and methodologies developed by and with Life Science core facilities
• Project & data management and quality control in and by Life Science core facilities
• Core facility administrative, human resource and financial management
• Teaching and training by and for Life Science core facilities
• Building networks, communities and lobbies involving Life Science core facilities.

NANBIOSIS participated in the CTLS 2016 Conference.

• Read More

Research Excellence Award by the Spanish Royal Society of Chemistry to Ramón Martínez, Scientific Director of Unit 26 of NANBIOSIS

The Governing Board of the Spanish Royal Society of Chemistry (SRSQ) has agreed to grant its Research Excellence Award 2016 to Dr. Ramón Martínez Máñez, Scientific Director of Unit 26 of NANBIOSIS and Scientific Director of CIBER-BBN, in recognition of the quality and innovation of its research in the design of chrome-fluorogenic detection probes and the development of new delivery systems and their impact on biomedical applications.

Martinez Máñez is co-authored of more than 330 scientific publications in international journals. His scientific work has been cited on over 13,000 occasions. It is among the 15 most cited authors in the area of Chemistry in Spain in recent years and currently has an index h of 56. He is currently Director of the Interuniversity Research Institute for Molecular Recognition and Technological Development (IDM) at the Politecnic University of Valencia. He has been coordinator of Project Evaluation Technology Area at the Generalitat Valenciana and member of the Committee of Experts for the Selection of Projects of the National Plan in 2010 and 2014 in the Thematic Area of Materials. Currently, he is also coordinator of the PhD Program in Chemistry and a member of the Steering Committee of the Doctoral School of the UPV, Co-chairman of the magazine ChemistryOpen published by Wiley and member of the International Advisory Board of the Chemistry journal Asian. Chem. J. and ChemPlusChem, published by Wiley

Nanbiosis U26-Research Excellence Award by the Spanish Royal Society of Chemistry to Ramón Martínez, Scientific Director of Unit 26 of NANBIOSIS

• Read More

Nanbiosis in the 2ª General Assambly of DRIVE project, Venice (16th-17th 2016)

Jesus Izco, Coordinator of NANBIOSIS and José Luis Pedraz, Scientific Director of Unit 10-Drug Formulation of NANBIOSIS and NanoBioCel Group of CIBER-BBN, participated in the 2ª General Assambly of DRIVE project, held in Venice, May 16th-17th 2016.

The second General Assembly of European project DRIVE “DIABETES-REVERSING-IMPLANTS FOR ENHANCED VIABILITY AND LONG TERM EFFICACY”, took place last 16 and 17 of May in San Servolo Island, Venice. Jesus Ciriza, from NanoBioCel group, presented the work scheduled for this first year and the results obtained.

The DRIVE, a 4-year project to be carried out by 14 European partners, among which is CIBER-BBN, develops biomaterials and new surgical devices to improve transplantation and survival of insulin-producing pancreatic islet for the treatment of diabetes.

CIBER-BBN participates in the project thought Unit 10 of NANBIOSIS with the role of:

-Development of hydrogel formulations for β-Gel

-Developing unlimited future sources of insulin-producing β-cells

-Testing β-cell function in β-Gel using 3D in vitro tissue model.

Jesus Izco, Coordinator of NANBIOSIS and José Luis Pedraz, Scientific Director of Unit 10-Drug Formulation of NANBIOSIS and NanoBioCel Group of CIBER-BBN, participated in the 2ª General Assambly of DRIVE project, held in Venice, May 16th-17th 2016.

• Read More

Last Friday, 27th May, the "Instituto de Investigación en Ingeniería de Aragón" held the "V Jornada de Jóvenes Investigadores" where phD students presented their works related to different areas: Industrial Technologies, Biomedical Engineering, Processes and Recycling and Information and Communications Technology.

Last Friday, 27th May, the “Instituto de Investigación en Ingeniería de Aragón” held the “V Jornada de Jóvenes Investigadores” where phD students presented their works related to different areas: Industrial Technologies, Biomedical Engineering, Processes and Recycling and Information and Communications Technology.

David Adolfo Sampedro Puente, member of the BSICoS, group coordinator of Unit 27 of NANBIOSIS, presented the work entitled “Unscented Kalman Filter for Unobservable Parameter Estimation in Heart Cell Signals”, supervised by Jesús Fernández Bes and Esther Pueyo Paules. This work shows a methodology to estimate unobservable parameters, such as the number of the different ion channel typologies located in the cardiomyocyte membrane, from action potential (AP) signals. This methodology was validated using synthetic AP signals simulated by stochastic computational cell models. In future, this methodology will be used to real signals, recorded in human cardiomyocytes, to help to the study of the AP temporal variability characterization.

Nanbiosis U27-Unscented Kalman Filter for Unobservable Parameter Estimation in Heart Cell Signals by David Sampedro

• Read More

You are here : Home / News (Page 81)